
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Government Dental College and Hospital, Vijayawada, Andra Pradesh, India
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotic Lozenge on Gingivitis and Periodontitis
Details : Lactobacillus Brevis CD2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Periodontitis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 30, 2014
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Government Dental College and Hospital, Vijayawada, Andra Pradesh, India
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inersan
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Sree Mookambika Institute of Dental Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis
Details : Inersan is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chronic Periodontitis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 26, 2014
Lead Product(s) : Inersan
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Sree Mookambika Institute of Dental Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Government Dental College and Hospital, India
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.
Details : Lactobacillus Brevis CD2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chronic Periodontitis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 23, 2014
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Government Dental College and Hospital, India
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Mahatma Gandhi PGI Dental Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis
Details : Lactobacillus Brevis CD2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chronic Periodontitis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 06, 2013
Lead Product(s) : Lactobacillus Brevis CD2
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Mahatma Gandhi PGI Dental Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Paracasei
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Post Graduate Institute of Medical Education and Research, Chandigarh
Deal Size : Inapplicable
Deal Type : Inapplicable
Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation
Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatic Encephalopathy.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 26, 2010
Lead Product(s) : Lactobacillus Paracasei
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Post Graduate Institute of Medical Education and Research, Chandigarh
Deal Size : Inapplicable
Deal Type : Inapplicable
